- NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with ...
Initial data readout on track for second half of 2025HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...
News-Medical.Net on MSN12h
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
M Co., Bioject Medical Technologies Inc., Valeritas Inc., Antares Pharma Inc., and Endo International PLC Lead the Competitive LandscapeDublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Needle Free ...
The Jones Healthcare and Technology Innovation Conference is recognized for bringing together a select group of innovative companies and institutional investors for a two-day event. The event will be ...
ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals with global rights for Increlex®, except for USA. This biologic product, the first biologic in ESTEVE's portfolio, is used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback